Cite

HARVARD Citation

    Gerson-Gurwitz, A. et al. (n.d.). Dissection of cancer therapy combinations in RTK driven tumors using zotatifin (eFT226), a potent and selective eIF4A inhibitor. European journal of cancer. pp. S56-. [Online]. 
  
Back to record